<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000824</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRAT 2</org_study_id>
    <nct_id>NCT00000824</nct_id>
  </id_info>
  <brief_title>A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients</brief_title>
  <official_title>A Pilot Study of HIV Specific Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients With CD4+ T Cells 100-350 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied&#xD;
      dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the&#xD;
      efficacy of these CTLs in helping the immune system to fight HIV.&#xD;
&#xD;
      With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and&#xD;
      lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs&#xD;
      generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the&#xD;
      body to recognize HIV more readily and increase immune response against the virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and&#xD;
      lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs&#xD;
      generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the&#xD;
      body to recognize HIV more readily and increase immune response against the virus.&#xD;
&#xD;
      Dendritic cells and lymphocytes are obtained from an HIV-negative sibling. HIV-specific CTLs&#xD;
      are generated from these cells and then infused into the HIV-infected patient monthly for 6&#xD;
      months. Siblings must be able to donate on multiple occasions, and patients are followed&#xD;
      every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lymphocytes, Activated</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HLA A2+.&#xD;
&#xD;
          -  Other HLA matching with sibling.&#xD;
&#xD;
          -  CD4 count 100-350 cells/mm3.&#xD;
&#xD;
          -  No active opportunistic infection or malignancy (other than cutaneous Kaposi's&#xD;
             sarcoma).&#xD;
&#xD;
          -  Current stable antiviral regimen.&#xD;
&#xD;
          -  Normal lab values and chest x-ray.&#xD;
&#xD;
        Donor siblings must have:&#xD;
&#xD;
          -  HLA A2+.&#xD;
&#xD;
          -  HIV negativity.&#xD;
&#xD;
          -  Good venous access.&#xD;
&#xD;
          -  Ability to donate on multiple occasions.&#xD;
&#xD;
          -  Negative status for hepatitis B and C.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Cytokines.&#xD;
&#xD;
          -  Systemic steroids.&#xD;
&#xD;
          -  IV pentamidine.&#xD;
&#xD;
          -  Investigational drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Univ School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <keyword>Immunotherapy, Adoptive</keyword>
  <keyword>T-Lymphocyte Subsets</keyword>
  <keyword>T-Lymphocytes, Cytotoxic</keyword>
  <keyword>Dendritic Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

